Works matching AU Zambello, R.

Results: 40
    1
    2
    3
    4
    5
    6
    7

    P36 BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY AGENT AND ONE ANTI-CD38 MONOCLONAL ANTIBODY: A RETRO-PROSPECTIVE ITALIAN OBSERVATIONAL STUDY

    Published in:
    2023
    By:
    • Offidani, M.;
    • Morè, S.;
    • Cavo, M.;
    • Derudas, D.;
    • Di Raimondo, F.;
    • Cuneo, A.;
    • Baldini, L.;
    • Della Pepa, R.;
    • Musso, M.;
    • Boccadoro, M.;
    • Musto, P.;
    • Belotti, A.;
    • Fioritoni, F.;
    • Di Renzo, N.;
    • Mele, A.;
    • Gamberi, B.;
    • De Paoli, L.;
    • Zambello, R.;
    • Grammatico, S.;
    • Brociner, M.
    Publication type:
    Abstract
    8
    9

    P49 A REAL‐WORLD RETROSPECTIVE‐PROSPECTIVE ANALYSIS OF EFFICACY AND SAFETY OF COMBINED IXAZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: THE NORTHERN ITALY EXPERIENCE.

    Published in:
    HemaSphere, 2023, v. 7, p. 37, doi. 10.1097/01.HS9.0000936324.92381.77
    By:
    • Furlan, A.;
    • Cea, M.;
    • Zambello, R.;
    • Pavan, L.;
    • Galli, M;
    • Clissa, C.;
    • Mangiacavalli, S.;
    • Cafro, A.;
    • Girlanda, S.;
    • Patriarca, F.;
    • Minotto, C.;
    • Bertoldero, G.;
    • Barilà, G.;
    • Pascarella, A.;
    • Lico, A.;
    • Paolini, R.;
    • Rabassi, N.;
    • Pescosta, N.;
    • Porrazzo, M.;
    • De Sabbata, G.
    Publication type:
    Article
    10

    P36 BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY AGENT AND ONE ANTI‐CD38 MONOCLONAL ANTIBODY: A RETRO‐PROSPECTIVE ITALIAN OBSERVATIONAL STUDY

    Published in:
    HemaSphere, 2023, v. 7, p. 30, doi. 10.1097/01.HS9.0000936272.88286.72
    By:
    • Offidani, M.;
    • Morè, S.;
    • Cavo, M.;
    • Derudas, D.;
    • Di Raimondo, F.;
    • Cuneo, A.;
    • Baldini, L.;
    • Della Pepa, R.;
    • Musso, M.;
    • Boccadoro, M.;
    • Musto, P.;
    • Belotti, A.;
    • Fioritoni, F.;
    • Di Renzo, N.;
    • Mele, A.;
    • Gamberi, B.;
    • De Paoli, L.;
    • Zambello, R.;
    • Grammatico, S.;
    • Brociner, M.
    Publication type:
    Article
    11
    12

    P07 BORTEZOMIB‐MELPHALAN‐PREDNISONE (VMP) VS. LENALIDOMIDE‐DEXAMETHASONE (RD) IN REAL‐LIFE MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR TRANSPLANT: UPDATED ANALYSIS OF THE RANDOMIZED PHASE IV REAL MM TRIAL.

    Published in:
    HemaSphere, 2023, v. 7, p. 12, doi. 10.1097/01.HS9.0000936156.32733.12
    By:
    • Larocca, A.;
    • D'Agostino, M.;
    • Giuliani, N.;
    • Antonioli, E.;
    • Zambello, R.;
    • Ronconi, S.;
    • Vincelli, I. D.;
    • Ciceri, F.;
    • Falcone, A. P.;
    • Michieli, M.;
    • Cattel, F.;
    • Capra, A.;
    • Grasso, M.;
    • Cafro, A. M.;
    • Bonello, F.;
    • Floris, R.;
    • Offidani, M.;
    • Sciorsi, E.;
    • Pietrantuono, G.;
    • Curci, P.
    Publication type:
    Article
    13

    PB1984: ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED 3‐YEAR FOLLOW‐UP OF AN ITALIAN, MULTICENTER, EXPERIENCE OUTSIDE OF CONTROLLED CLINICAL TRIALS.

    Published in:
    HemaSphere, 2022, v. 6, p. 1856, doi. 10.1097/01.HS9.0000850772.23648.13
    By:
    • Bruzzese, A.;
    • Derudas, D.;
    • Galli, M.;
    • Martino, E. A.;
    • Rocco, S.;
    • Conticello, C.;
    • Califano, C.;
    • Giuliani, N.;
    • Mangicavalli, S.;
    • Farina, G.;
    • Lombardo, A.;
    • Brunori, M.;
    • Rossi, E.;
    • Antonioli, E.;
    • Ria, R.;
    • Zambello, R.;
    • Di Renzo, N.;
    • Mele, G.;
    • Marcacci, G.;
    • Pietrantuono, G.
    Publication type:
    Article
    14
    15
    16
    17
    18
    19
    20
    21
    22

    LONG‐TERM EFFICACY AND SAFETY OF LENALIDOMIDE MAINTENANCE IN PATIENTS WITH RELAPSED DIFFUSE LARGE B‐CELL LYMPHOMA WHO ARE NOT ELIGIBLE FOR AUTOLOGOUS TRANSPLANTATION (ASCT).

    Published in:
    Hematological Oncology, 2019, v. 37, p. 256, doi. 10.1002/hon.65_2630
    By:
    • Ferreri, A.J.;
    • Sassone, M.C.;
    • Angelillo, P.;
    • Zaja, F.;
    • Re, A.;
    • Spina, M.;
    • Di Rocco, A.;
    • Fabbri, A.;
    • Stelitano, C.;
    • Frezzato, M.;
    • Rusconi, C.;
    • Zambello, R.;
    • Arcari, A.;
    • Bertoldero, G.;
    • De Lorenzo, D.;
    • Volpetti, S.;
    • Calimeri, T.;
    • Perrone, S.;
    • Cecchetti, C.;
    • Ciceri, F.
    Publication type:
    Article
    23
    24

    LONG‐TERM EFFICACY AND SAFETY OF LENALIDOMIDE MAINTENANCE IN PATIENTS WITH RELAPSED DIFFUSE LARGE B‐CELL LYMPHOMA WHO ARE NOT ELIGIBLE FOR AUTOLOGOUS TRANSPLANTATION (ASCT).

    Published in:
    Hematological Oncology, 2019, v. 37, p. 256, doi. 10.1002/hon.65_2630
    By:
    • Ferreri, A.J.;
    • Sassone, M.C.;
    • Angelillo, P.;
    • Zaja, F.;
    • Re, A.;
    • Spina, M.;
    • Di Rocco, A.;
    • Fabbri, A.;
    • Stelitano, C.;
    • Frezzato, M.;
    • Rusconi, C.;
    • Zambello, R.;
    • Arcari, A.;
    • Bertoldero, G.;
    • De Lorenzo, D.;
    • Volpetti, S.;
    • Calimeri, T.;
    • Perrone, S.;
    • Cecchetti, C.;
    • Ciceri, F.
    Publication type:
    Article
    25
    26
    27
    28
    29
    30

    Immunologic abnormalities in angioimmunoblastic lymphadenopathy.

    Published in:
    1987
    By:
    • Pizzolo, Giovanni;
    • Vinante, Fabrizio;
    • Agostini, Carlo;
    • Zambello, Renato;
    • Trentin, Livio;
    • Masciarelli, Maria;
    • Chilosi, Marco;
    • Benedetti, Fabio;
    • Dazzi, Francesco;
    • Todeschini, Giuseppe;
    • Rossi, Anita De;
    • Semenzato, Gianpietro;
    • Pizzolo, G;
    • Vinante, F;
    • Agostini, C;
    • Zambello, R;
    • Trentin, L;
    • Masciarelli, M;
    • Chilosi, M;
    • Benedetti, F
    Publication type:
    journal article
    31
    32

    Rituximab-responsive CIDP.

    Published in:
    2004
    By:
    • Briani, C.;
    • Zara, G.;
    • Zambello, R.;
    • Trentin, L.;
    • Rana, M.;
    • Zaja, F.
    Publication type:
    Letter
    33
    34

    Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.

    Published in:
    1994
    By:
    • Zambello, Renato;
    • Trentin, Livio;
    • Cerutti, Andrea;
    • Enthammer, Christine;
    • Milani, Antonella;
    • Franceschi, Tiziano;
    • Messina, Chiara;
    • Cetto, Gian Luigi;
    • Agostini, Carlo;
    • Semenzato, Gianpietro;
    • Zambello, R;
    • Trentin, L;
    • Cerutti, A;
    • Enthammer, C;
    • Milani, A;
    • Franceschi, T;
    • Messina, C;
    • Cetto, G L;
    • Agostini, C;
    • Semenzato, G
    Publication type:
    journal article
    35
    36
    37

    Cyclophosphamide as a first-line therapy in LGL leukemia.

    Published in:
    Leukemia (08876924), 2014, v. 28, n. 5, p. 1134, doi. 10.1038/leu.2013.359
    By:
    • Moignet, A;
    • Hasanali, Z;
    • Zambello, R;
    • Pavan, L;
    • Bareau, B;
    • Tournilhac, O;
    • Roussel, M;
    • Fest, T;
    • Awwad, A;
    • Baab, K;
    • Semenzato, G;
    • Houot, R;
    • Loughran, T P;
    • Lamy, T
    Publication type:
    Article
    38
    39
    40